JP2002502836A5 - - Google Patents

Download PDF

Info

Publication number
JP2002502836A5
JP2002502836A5 JP2000530488A JP2000530488A JP2002502836A5 JP 2002502836 A5 JP2002502836 A5 JP 2002502836A5 JP 2000530488 A JP2000530488 A JP 2000530488A JP 2000530488 A JP2000530488 A JP 2000530488A JP 2002502836 A5 JP2002502836 A5 JP 2002502836A5
Authority
JP
Japan
Prior art keywords
xii
embedded image
vii
prodrug
hydroxylated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000530488A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002502836A (ja
JP4642226B2 (ja
Filing date
Publication date
Priority claimed from GBGB9802522.4A external-priority patent/GB9802522D0/en
Application filed filed Critical
Priority claimed from PCT/GB1999/000155 external-priority patent/WO1999040056A1/en
Publication of JP2002502836A publication Critical patent/JP2002502836A/ja
Publication of JP2002502836A5 publication Critical patent/JP2002502836A5/ja
Application granted granted Critical
Publication of JP4642226B2 publication Critical patent/JP4642226B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2000530488A 1998-02-06 1999-02-02 ヒドロキシル化により活性化されたプロドラッグ Expired - Fee Related JP4642226B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9802522.4A GB9802522D0 (en) 1998-02-06 1998-02-06 Hydroxylation activated prodrugs
US09/115,015 US6214886B1 (en) 1998-02-06 1998-07-14 Hydroxylation activated prodrugs
US09/115,015 1998-07-14
US9802522.4 1998-07-14
PCT/GB1999/000155 WO1999040056A1 (en) 1998-02-06 1999-02-02 Hydroxylation activated prodrugs

Publications (3)

Publication Number Publication Date
JP2002502836A JP2002502836A (ja) 2002-01-29
JP2002502836A5 true JP2002502836A5 (cg-RX-API-DMAC7.html) 2006-03-16
JP4642226B2 JP4642226B2 (ja) 2011-03-02

Family

ID=26313066

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000530488A Expired - Fee Related JP4642226B2 (ja) 1998-02-06 1999-02-02 ヒドロキシル化により活性化されたプロドラッグ

Country Status (9)

Country Link
US (2) US6677383B1 (cg-RX-API-DMAC7.html)
EP (1) EP1051383B1 (cg-RX-API-DMAC7.html)
JP (1) JP4642226B2 (cg-RX-API-DMAC7.html)
AT (1) ATE272040T1 (cg-RX-API-DMAC7.html)
AU (1) AU2173899A (cg-RX-API-DMAC7.html)
CA (1) CA2319836C (cg-RX-API-DMAC7.html)
DE (1) DE69918950T2 (cg-RX-API-DMAC7.html)
ES (1) ES2226332T3 (cg-RX-API-DMAC7.html)
WO (1) WO1999040056A1 (cg-RX-API-DMAC7.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69918950T2 (de) 1998-02-06 2005-07-28 De Montfort University Durch hydroxylierung aktivierte medikamentvorstufen
GB2334256A (en) 1998-02-12 1999-08-18 Univ Montfort Hydroxylation activated prodrugs
ATE444960T1 (de) * 1999-12-06 2009-10-15 Welichem Biotech Inc Polyhydroxystilbene und -stilbenoxide als antipsoriasismittel und proteinkinasehemmer
US7321050B2 (en) 1999-12-06 2008-01-22 Welichem Biotech Inc. Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxy stilbenes and novel stilbene derivatives and analogues
GB0007401D0 (en) 2000-03-27 2000-05-17 Cancer Res Campaign Tech Substituted chalcones as therapeeutic compounds
AU2001248201B2 (en) * 2000-04-13 2006-12-14 Hsc Research And Development Limited Partnership Compounds for modulating cell proliferation
US7626026B2 (en) 2001-02-22 2009-12-01 University Of Bradford Pyrrolo-indole and pyrrolo-quinoline derivatives as prodrugs for tumour treatment
JP4862120B2 (ja) 2001-02-22 2012-01-25 ユニヴァーシティ オブ ブラッドフォード 腫瘍治療のためのプロドラッグとしてのベンズ−インドールおよびベンゾ−キノリン誘導体
US6589997B2 (en) * 2001-06-29 2003-07-08 North Shore-Long Island Jewish Health System Small-molecule modulators of hepatocyte growth factor/scatter factor activities
GB0123780D0 (en) 2001-10-03 2001-11-21 Cancer Res Ventures Ltd Substituted chalcones as therapeutic agents
GB0123777D0 (en) 2001-10-03 2001-11-21 Cancer Res Ventures Ltd Substituted chalcones as therapeutic agents
US6919324B2 (en) * 2001-10-26 2005-07-19 Oxigene, Inc. Functionalized stilbene derivatives as improved vascular targeting agents
GB0126889D0 (en) * 2001-11-08 2002-01-02 Paterson Inst For Cancer Res Compounds and their uses
AU2003250701A1 (en) * 2002-07-31 2004-02-16 Wayne R. Danter Protein tyrosine kinase inhibitors
CA2542007C (en) * 2002-10-09 2010-06-29 Wayne R. Danter Protein tyrosine kinase inhibitors
MXPA05008298A (es) * 2003-02-04 2005-09-20 Yakult Honsha Kk Inhibidor de la proteina de resistencia a cancer de mama.
WO2005092904A1 (en) * 2004-03-26 2005-10-06 Hsc Research And Development Limited Partnership Novel compounds for modulating cell proliferation
AU2006232435B8 (en) 2005-03-30 2011-09-15 Kabushiki Kaisha Yakult Honsha BCRP/ABCG2 inhibitor
WO2008083491A1 (en) 2007-01-11 2008-07-17 Critical Outcome Technologies Inc. Compounds and method for treatment of cancer
US7784455B1 (en) * 2007-09-18 2010-08-31 Chong Carlton Le Loong Reusable pellet shooting grenade
US8466151B2 (en) * 2007-12-26 2013-06-18 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
GB0803071D0 (en) * 2008-02-20 2008-03-26 Care Technologies Inc Cancer detection methods and techniques
EP3023426A1 (en) * 2008-07-17 2016-05-25 Critical Outcome Technologies, Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
GB0907551D0 (en) 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
WO2011120153A1 (en) 2010-04-01 2011-10-06 Critical Outcome Technologies Inc. Compounds and method for treatment of hiv
KR20200118827A (ko) 2018-02-02 2020-10-16 마베릭스 온콜로지, 잉크. 젬시타빈 모노포스페이트의 소분자 약물 컨쥬게이트

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6176433A (ja) * 1984-09-21 1986-04-18 Toyobo Co Ltd 新規なカルコン誘導体
US5773435A (en) 1987-08-04 1998-06-30 Bristol-Myers Squibb Company Prodrugs for β-lactamase and uses thereof
AU632992B2 (en) * 1987-12-24 1993-01-21 Yissum Research Development Company Of The Hebrew University Of Jerusalem Pharmaceutical compositions comprising benzylidene- and cinnamylidene-malononitrile derivatives for the inhibition of proliferative processes in mammalian cells, certain such novel compounds and their preparation
US5287386A (en) 1991-03-27 1994-02-15 Thinking Machines Corporation Differential driver/receiver circuit
US5430062A (en) * 1992-05-21 1995-07-04 Research Corporation Technologies, Inc. Stilbene derivatives as anticancer agents
DE4236237A1 (de) 1992-10-27 1994-04-28 Behringwerke Ag Prodrugs, ihre Herstellung und Verwendung als Arzneimittel
DE4309344A1 (de) 1993-03-23 1994-09-29 Gerhard Prof Dr Eisenbrand Antineoplastische Mittel mit verstärkter Wirksamkeit
US5276058A (en) * 1993-06-09 1994-01-04 Nippon Hypox Laboratories Incorporated 3,4-dihydroxychalcone derivatives
EP0647450A1 (en) 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
FR2710798B1 (fr) 1993-09-27 1995-11-10 Alcatel Mobile Comm France Chaîne d'amplification en mode de courant, amplificateur opérationnel, cellule de gain et élément d'amplification correspondants.
JPH08188546A (ja) * 1995-01-04 1996-07-23 Kyowa Hakko Kogyo Co Ltd カルコン誘導体
GB9519490D0 (en) 1995-09-25 1995-11-29 Melvin William T Use of a cytochrome P450 enzyme in tumour cells as a marker and target
US5966032A (en) 1996-09-27 1999-10-12 Northern Telecom Limited BiCMOS transceiver (driver and receiver) for gigahertz operation
GB9802522D0 (en) 1998-02-06 1998-04-01 Montford University De Hydroxylation activated prodrugs
DE69918950T2 (de) 1998-02-06 2005-07-28 De Montfort University Durch hydroxylierung aktivierte medikamentvorstufen
GB2334256A (en) 1998-02-12 1999-08-18 Univ Montfort Hydroxylation activated prodrugs
CA2319837C (en) 1998-02-12 2009-10-27 De Montfort University Hydroxylation activated drug release

Similar Documents

Publication Publication Date Title
JP2002510633A5 (cg-RX-API-DMAC7.html)
JP2003531118A5 (cg-RX-API-DMAC7.html)
CA2319836A1 (en) Hydroxylation activated prodrugs
JP2002508347A5 (cg-RX-API-DMAC7.html)
JP2002513793A5 (cg-RX-API-DMAC7.html)
RU2003100076A (ru) Противосудорожные производные, используемые для профилактики развития сахарного диабета и синдрома х
JP2001520998A5 (cg-RX-API-DMAC7.html)
JP2003533479A5 (cg-RX-API-DMAC7.html)
JP2002509153A5 (cg-RX-API-DMAC7.html)
MXPA03008223A (es) Compuesto para tratamiento de enfermedades inflamatorias.
JP2008518890A5 (cg-RX-API-DMAC7.html)
IL131172A (en) 1-phenyl-4-benzylpiperazines: dopamine receptor subtype specific ligands (d4)
JP2003502367A5 (cg-RX-API-DMAC7.html)
WO2002092072A3 (en) Drugs for the treatment of the alzheimer disease
JP2002506864A5 (cg-RX-API-DMAC7.html)
JP2001525394A5 (cg-RX-API-DMAC7.html)
JP2003529542A5 (cg-RX-API-DMAC7.html)
CA2403900A1 (en) Substituted chalcones as therapeutic compounds
JP2004315496A5 (cg-RX-API-DMAC7.html)
JP2008534592A5 (cg-RX-API-DMAC7.html)
CA2458318A1 (en) Wortmannin analogs and methods of using same
JP2001519413A5 (cg-RX-API-DMAC7.html)
JP2004538314A5 (cg-RX-API-DMAC7.html)
JP2005516035A5 (cg-RX-API-DMAC7.html)
AU2001246999A1 (en) New neurokinin antagonists for use as medicaments